Search research articles
Contact Us
Filters
Showing results (1-10 of 7) with videos related to
Page
of 1
Sort By:
Scientific Data
|
November 1, 2017
A dataset quantifying polypharmacy in the United States
Katie J Quinn, Nigam H Shah
Cancer Research Communications
|
July 29, 2025
Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Samantha I Liang, Zoe Quandt, Sara Wienke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 23, 2020
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
Han Si, Michael Kuziora, Katie J Quinn, et al.
Journal for Immunotherapy of Cancer
|
September 22, 2025
Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy
Hillary S Andrews, Nevine Zariffa, Katherine K Nishimura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2020
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer
Charu Aggarwal, Jeffrey C Thompson, Austin L Chien, et al.
Journal for Immunotherapy of Cancer
|
March 29, 2020
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
Diana M Merino, Lisa M McShane, David Fabrizio, et al.
JCO Precision Oncology
|
August 11, 2022
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Diana Merino Vega, Katherine K Nishimura, Névine Zariffa, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 7) with videos related to
Sort By:
Page
of 1
Scientific Data
|
November 1, 2017
A dataset quantifying polypharmacy in the United States
Katie J Quinn, Nigam H Shah
Cancer Research Communications
|
July 29, 2025
Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Samantha I Liang, Zoe Quandt, Sara Wienke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 23, 2020
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
Han Si, Michael Kuziora, Katie J Quinn, et al.
Journal for Immunotherapy of Cancer
|
September 22, 2025
Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy
Hillary S Andrews, Nevine Zariffa, Katherine K Nishimura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2020
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer
Charu Aggarwal, Jeffrey C Thompson, Austin L Chien, et al.
Journal for Immunotherapy of Cancer
|
March 29, 2020
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
Diana M Merino, Lisa M McShane, David Fabrizio, et al.
JCO Precision Oncology
|
August 11, 2022
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Diana Merino Vega, Katherine K Nishimura, Névine Zariffa, et al.
Page
of 1